Squarepoint
CAPR icon

Squarepoint’s Capricor Therapeutics CAPR Stock Holding History

Squarepoint’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,600
Closed -$146K – 4646
2024
Q4 		$146K Buy
+10,600
New +$186K ﹤0.01% 4579

Other funds holding CAPR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
HBK Sorce Advisory
HBK Sorce Advisory Erie, Pennsylvania $5.18B AUM 12.38% 1-Year Est. Return
Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Black Diamond Financial
Black Diamond Financial Towson, Maryland $1.18B AUM 15.24% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Squarepoint's CAPR Position: Q3 2026 in Review

Squarepoint increased its Capricor Therapeutics (CAPR) stake by 1,111% in Q3 2026, buying an estimated $2.43M and bringing the position to 238,892 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #2094.

Squarepoint first reported a position in CAPR in Q2 2024 and has held it in 7 quarters since. 52 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

  • Squarepoint held 238,892 shares of Capricor Therapeutics worth $2.26M as of Q3 2026.
  • Squarepoint bought 219,161 Capricor Therapeutics shares in Q3 2026, an estimated $2.43M.
  • Capricor Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q3 2026, its #2094 holding.
  • Squarepoint first reported a position in Capricor Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 52 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.